Compare AbbVie Inc (ABBV) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

EWU trades at $47.22, showing slight daily gains with a bullish technical outlook supported by moving averages. The ETF reflects UK market exposure, with recent news highlighting political uncertainty and economic challenges. Technical indicators show mixed signals with RSI suggesting potential overbought conditions near-term.

The outlook remains cautious due to UK political instability and economic headwinds, though potential short-squeeze dynamics and record European equity performances offer upside. Key risks include sterling weakness and domestic policy shifts. Investors should weigh geopolitical factors against valuation discounts in UK assets.